Search results for "Rubella vaccine"

showing 10 items of 16 documents

Factors associated with poor adherence to MMR vaccination in parents who follow vaccination schedule.

2014

Due to median vaccination coverage far from elimination level, Italy is still an European country with high number of measles cases per million of people. In this study we explored potential socioeconomic, medical and demographic factors which could influence the propensity of family members for measles vaccination schedule. A cross-sectional study was performed through a questionnaire administered to the parents of children who received the first dose of MMR vaccine in two different vaccination centers in the Palermo area from November 2012 to May 2013. Overall, the role played by internet (OR 19.8 P = 0.001) and the large number of children in a family (OR 7.3 P ≤ 0.001) were the factors …

AdultMaleParentsPediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella VaccineVaccination scheduleCross-sectional studyImmunologyMMR vaccineSettore MED/42 - Igiene Generale E ApplicataMeaslesMedication AdherencechildrenSurveys and QuestionnairesmedicineImmunology and AllergyHumansmeaslebirth orderSocioeconomic statusPharmacologypersonal decisionbusiness.industryVaccinationInfant NewbornInfantmedicine.diseaseVaccinationBirth orderCross-Sectional Studiesvaccination refuseSocioeconomic FactorsItalyfamily memberChild PreschoolFemaleinternetbusinessMeasles-Mumps-Rubella VaccineDemographyResearch PaperMeasles
researchProduct

Maturation of IgG avidity to individual rubella virus structural proteins.

2001

Background: the structural proteins of rubella virus, the capsid protein C and the envelope glycoproteins E1 and E2 were produced in lepidopteran insect cells using baculovirus expression vectors. The C-terminal ends of the corresponding proteins were fused to a polyhistidine tag for easy and gentle purification by metal ion affinity chromatography. Objectives: to investigate the maturation of natural and vaccinal IgG avidity against individual authentic and recombinant rubella virus (RV) structural proteins. Study design the analysis was carried out using a modified immunoblotting technique where the purified baculovirus-expressed proteins were compared with authentic rubella virus protein…

Antibody Affinitymedicine.disease_causeAntibodies ViralVirusbaculovirusViral envelopeViral Envelope ProteinsavidityVirologyImmunoblot AnalysisexpressionmedicineHumansAvidityRubella VaccineRubellachemistry.chemical_classificationbiologyViral Core ProteinsVaccinationstructural proteinsRubella virusbiology.organism_classificationVirologyInfectious DiseasesCapsidchemistryImmunoglobulin GTogaviridaeGlycoproteinrubella virusRubella virusJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
researchProduct

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

2019

Background: Successful tyrosine-kinase inhibitors (TKIs) discontinuation has been obtained in some patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML). Careful molecular monitoring after discontinuation is the key to guarantee the safety, in terms of prompt resumption of therapy according to retreatment threshold criteria. It was observed that the majority of relapses usually occur during the first 6 months after TKI discontinuation [Saussele S, Lancet Oncol 2018; Etienne G, JCO 2017], accounting for the monthly quantitative PCR (qPCR) that all prospective protocols included in the trial design at least during the first half-year. Two studies [Kong HJ, Cancer 2017; Shanmugan…

Brachial Plexus NeuritisPediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinebusiness.industryImmunologyMyeloid leukemiaCancerCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionDiscontinuationlawRetrospective analysisMedicinebusinessPolymerase chain reactionBlood
researchProduct

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spa…

2013

Abstract Background Given the concurrent administration of multiple vaccines during routine pediatric immunizations, efforts to elucidate the potential interference of any vaccine on the immune response to the concomitantly administered antigens are fundamental to prelicensure clinical research. Methods This phase 3 randomized controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) versus 7-valent PCV (PCV7) assessed immune responses of concomitantly administered meningococcal group C conjugated to diphtheria toxin cross-reactive material 197 (MnCCV-CRM 197 ) in a 2-dose infant series and 15-month toddler dose. Results 619 subjects were randomized, 315 to PCV13 and 304 to PCV7.…

MaleHeptavalent Pneumococcal Conjugate VaccineMeasles-Mumps-Rubella VaccineDrug-Related Side Effects and Adverse ReactionsMeningococcal VaccinesPneumococcal conjugate vaccinePneumococcal VaccinesConjugate vaccineMedicineHumansToddlerImmunization ScheduleGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityVaccinationPublic Health Environmental and Occupational HealthAntibody titerInfantAntibodies BacterialHealthy VolunteersTiterInfectious DiseasesTolerabilitySpainImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.

2014

Abstract Background In July 2006, Priorix-Tetra™, a combined measles-mumps-rubella-varicella (MMRV) vaccine, was licensed in Germany. Since a postlicensure study had shown a more than twofold elevated risk of febrile convulsions (FC) after first dose vaccination with the combined MMRV vaccine ProQuad ® compared to separately administered MMR and V vaccines (MMR+V), the Paul-Ehrlich-Institute, the German regulatory agency for vaccine licensing and safety, requested a study investigating the risk of FC for Priorix-Tetra™. Methods We performed a matched cohort study based on claims data of more than 17 million insurees in the German Pharmacoepidemiological Research Database. All children born …

MalePediatricsmedicine.medical_specialtymedicine.vaccineSeizures FebrileChickenpox VaccineCohort StudiesGermanymedicineClinical endpointHumansVaccines CombinedFebrile convulsionsMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryConfoundingVaccinationPublic Health Environmental and Occupational HealthInfantOdds ratioVaccinationInfectious DiseasesImmunizationRelative riskChild PreschoolMolecular MedicineFemalebusinessMeasles-Mumps-Rubella VaccineVaccine
researchProduct

Post-vaccine measles in a child with concomitant influenza, Sicily, Italy, March 2015

2015

We describe the occurrence of measles in an 18 month-old patient in Sicily, Italy, in March 2015, who received the first dose of a measles-containing vaccine seven days before onset of prodromal symptoms. Measles virus infection was confirmed by PCR and detection of specific immunoglobulin; viral genotyping permitted the confirmation of a vaccine-associated illness. The patient had a concurrent influenza virus infection, during a seasonal epidemic outbreak of influenza.

MaleTime FactorsMeasles-Mumps-Rubella VaccineGenotypeEpidemiologyAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataMeaslesPolymerase Chain ReactionVirusMeasles virusChickenpox VaccineVirologymedicineHumansVaccines CombinedGenotypingChickenpox Vaccinebiologybusiness.industryPublic Health Environmental and Occupational HealthInfantmedicine.diseasebiology.organism_classificationVirologyMEASLES INFLUENZA VACCINESImmunoglobulin MItalyImmunoglobulin MMeasles virusConcomitantbiology.proteinFemalebusinessMeasles-Mumps-Rubella VaccineMeasles
researchProduct

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

Withdrawal of a mumps vaccine: Reasons and impacts

1993

Measles-Mumps-Rubella Vaccinebusiness.industryMeasles VaccineInfantMumps VaccineVirologyMeningitis BacterialDrug CombinationsRubella vaccineMumps vaccineChild PreschoolPediatrics Perinatology and Child HealthProduct Surveillance PostmarketingmedicineHumansRubella VaccineMeasles vaccineViral diseasebusinessMeasles-Mumps-Rubella VaccineCerebrospinal FluidRetrospective Studiesmedicine.drugEuropean Journal of Pediatrics
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-anal…

2016

ABSTRACT Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance. The aim of this paper is to identify the main factors associated with partial and full MMR vaccination uptake in European parents, and combine the different studies to obtain overall quantitative measures. This activity is included within the ESCULAPIO project, funded by the Italian Ministry of Health. ORs and CIs were extracted, sources of heterogeneity explored and publication bias assessed. Forty-five papers were retrieved for the qualitative study, 26 of which were i…

ParentsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinedeterminant; measles; mumps and rubella; parents; uptake; vaccine; Immunology and Allergy; Immunology; PharmacologyImmunologyReviewdeterminantSettore MED/42 - Igiene Generale E ApplicataMMR vaccineRubellaMeasles03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsHumansmeaslesmeasleImmunology and AllergyMedicinemumps and rubella030212 general & internal medicineMumpsRubellaPharmacologyPracticebusiness.industryHealth KnowledgeVaccinationPublication biasPatient Acceptance of Health Caremedicine.diseaseEuropeVaccinationparentdeterminant; measles; mumps and rubella; parents; uptake; vaccine; Europe; Health Knowledge Attitudes Practice; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Patient Acceptance of Health Care; Rubella; Vaccination; ParentsAttitudesuptakeMeta-analysisMarital statusbusinessMeasles-Mumps-Rubella VaccineDemographyHuman Vaccines &amp; Immunotherapeutics
researchProduct